

References

- Aboud N (2001):* Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. *J. Neurosci*; 309: 197-201.
- Adams IB and Martin B.R. (2002):* Cannabis: Pharmacology and toxicology in animals and humans, *Addiction*, 91 (11): 1585-1614.
- Adams IB Noy YI and Tostowaryk W (1996):* The effects of marijuana, alone and in combination with alcohol, on driving an instrumented car, *Proceedings of the 10 International Conference on Alcohol, Drugs and Traffic Safety*, Amsterdam, 203-206.
- Adlaf EM and Paglia A (2006):* Drug Use among Ontario Students 1997-2001. Findings from the OSDUS. Toronto: Centre for Addiction and Mental Health, page 134.
- Adlaf EM, Mann RE, Paglia A, et al. (2003):* Drinking, cannabis use and driving among Ontario students. *Canadian Medical Association J*; 168 (5): 565-566.
- Adlaf E, Paglia-Boak A, et al. (2006):* Cannabis. Cannabis and driving: A review and acommentary. *Road Safety Research Report No 12*, DETR, London.10(6): 150-155.
- Agurell S and Leander K (1999):* Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) smoking, *Acta*

References

- Pharmaceutica Suecica, (8): 391-402.
- Agurell S, Halldin M, Lindgren JE, et al. (1996):*** Pharmacokinetics and metabolism of delta tetrahydrocannabinol and other cannabinoids with emphasis on man. *Pharm . Rev* ,(38): 21-43.
- Allardice P (1993):*** A - Z of Companion Planting. Cassell. *Br.Med.J*; (288):1047-9.
- Ames F and Franc S (1998):*** A clinical and metabolic study of acute intoxication with cannabis sativa and its role in the model psychoses, *J: Men . Sci* ; (104) :972-99.
- Amtmann D, Weydt P, Johnson KL, Jensen MP, Carter GT, et al.(2004):*** Survey of *cannabis* use in patients with *amyotrophic lateral sclerosis*. *Am. J. of Hospice and Palliative Care*; (21): 95-104.
- Andeasson S (2001):*** Cannabis and schizophrenia: A longitudinal study of Swedish conscripts, *The Lancet*, (1):1483-1485.
- Ashton CH (2001):*** Pharmacology of cannabis: a brief review. *B .J. S*; (178): 101-106.
- Axelrod J and Felder CC (1998):*** Cannabinoid receptors and their endogenous agonist, anandamide, *Neurochem. Res.*, 23 (5): 575-581.
- Barbers RG (2000):*** Differential examination of bronchoalveolar lavage cells in tobacco cigarette and marijuana smokers, *American Rev. Res.Dis*; (135):1271-1275.
- Barlew (2006):*** Recent study on cannabisiby. Candian government. *J*.
-

References

Med;(158) : 396-601.

Barsky SH, Roth MD, Kleerup EC, Simmons M, Tashkin DP, et al. (1998): Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco, J. N. Can.Institute ;(90): 1198-1205.

Baselt RC. (2002): Disposition of toxic drugs and chemical in man, 6th ed. Faster city, CA: Biomedical Publication. 1004-1007.

Beirness DJ, Simpson HM, Desmond K, et al. (2003): The Road Safety Monitor 2002: Drugs and Driving. Ottawa: Traffic Injury Research Foundation., 17 (4): 323 -345.

Bell J (1998) On the haschisch or cannabis indica, Boston Med. and Surg. J; (56):209-16, 229-36.

Bell L and John G (1999): A Plant Fibres for Paper making. Liliaceae Press A good practical section on how to make paper on a small scale plus details of about 75 species (quite a few of them tropical) that can be used.

Ben AM (2001):Pschodysleptic Drugs: Cannabis and Hallucinogens, University of Montreal.J.Appl Toxicol;16(5): 397-400.

Berghaus G and Guo BL (1995): Medicines and driver fitness - findings from a meta-analysis of experimental studies as basic information to patients, physicians and experts. In: Kloeden, C.N., McLean, A.J. (Eds.), Alcohol, Drugs, and Traffic Safety - T'95: proceedings of the 13th International Conference on Alcohol, Drugs and Traffic Safety, Adelaide, pp. 295-300.

References

- Block RI (2001):*** Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women, *Drug and Alcohol Dependence* , J.Appl Toxicol ; (28):121-128.
- Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ, et al. (2004):*** An open label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis *J.Urol* ;10(4): 425-433.
- Brookoff D, Cook CS, Williams C, Mann CS, et al. (1994):*** Testing reckless drivers.*NEJM*; 332:892-893.
- Burn LD and Ineck J (2006):*** Effects of smoked marijuana on human performance: A critical review, in *Marijuana/Cannabinoids: Neurobiology and Neurophysiology*, Murphy L. and Bartke A. (eds.), CRC Press, Boca Raton, 387-423.
- Carta G and Nava L and Gessa GL (1999):*** Control of Pain inhibition by endogenocy. *Cannabinoids.J. Nat*; 394 (6690):277 – 281.
- Chatterjee W (2002):*** A dramatic response to inhaled cannabis in a woman with central thalamic pain and dystonia. *The Journal of Pain and Symptoms Management*, (24): 4-6.
- Chopra RN, Nayar SL and Chopra IC, et al. (1996):*** Glossary of Indian Medicinal Plants (Including the Supplement). Council of Scientific and Industrial Research, New Delhi. *PI. Med*, 38(2): 174-176.
- Cichewicz, DL, Martin ZC, Smith FL. Welch SP (1999):*** Enhancement
-

References

- of μ opioid antinociception by oral Delta tetrahydrocannabinol: dose-response analysis and receptor identification. *J. Pharmacol Exp. Ther*; **289**: 859-867.
- Coates RA (2000):** Cofactors of progression to acquired immunodeficiency syndrome in a cohort of male sexual contacts of men with human immunodeficiency virus disease, *Ame .J. of Epidemiol* ; vol. 132, 717-722.
- Cochetto DM, and Owens SM (2001):** Relationship between plasma delta-9-THC concentration and pharmacological effects in man, *Psychopharmacology*, 75: 158-164.
- Cone EL and Johnson RE (1996):** Contact high and urinary cannabinoid excretion after passive exposure to marijuana smoke. *Clin Pharmacol Ther* (40): 245-256.
- Croxford A and Yamamura N (2005):** Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases. *J. Neuroimmunol* ;166: 3-18.
- Daisley H, Jones-Le Cointe A, Hutchinson G and Simmons V (2008):** Fatal cardiac toxicity temporally related to poly-drug abuse. *Vet Hum. Toxicol* ,40(1):21-2.
- Dastur JF (1992):** Cannabis and the brain. *Aust N.Z.J; psychiatry*, 30: 179-183.
- David B (2004):** "Hepatitis C – Current state of the art and future directions *Med Scape Today*.
- Davis JP and Ramsey HH (2001):** "Antiepileptic action of marihuana-active substances, *Federat. Proc.*, (8) : 284 – 85.
-

References

- Day NL (2004):** Effect of prenatal marijuana exposure on the cognitive development of offspring at age three, *Neurotoxicology and Teratology*, 16: 1100-1110.
- Devane WA, Hanus L, Breuer A, Pertwee RG, et al. (1992):** Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor, *Science*, 258 : 1946-1949.
- Di Marzo V and Fontana A (2006):** Formation and inactivation of endogenous cannabinoid anandamide in central neurons, *Nature* 372: 686-691.
- Dornbush RL (2004):** The long-term effects of cannabis use, in *Marijuana: Effects on Behaviour*, Miller L.L. (ed.), New York, Academic Press.300-305.
- Duke JA (2003):** Handbook of Energy Crops - Published only on the Internet, excellent information on a wide range of plants,7 : 289-400.
- Duke JA and Ayensu ES (1995):** Keys for the identification of seedlings of some prominent woody species in eight forest types in Puerto Rico. *Ann. Mo. Bot. Gard.* 52(3):314-350.
- Ehrenkranz JRL and Hembree WC (2006):** Effects of marijuana on male reproductive function, *Psychiatric Annals*, 16: 243-249.
- Ellis BM, Mand MA and Judson BA (1985):** Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. *Clin. Pharmacol. Ther.* 38: 572-578.
- Ellis EF, Moore SF and Willoughby KA. (1995):** Anandamide and

References

delta 9-THC dilation of cerebral arterioles is blocked by indomethacin *Am J Physiol*, 269(6 Pt 2):H1859-64.

El-Mallakh RF, (1997): Marijuana and Migraine, Headache, J. Neurol. Neurosurg; Psychiatry, 53:436.

Eubanks LM, Rogers CJ, Beuscher AE 4th, Koob GF, Olson AJ, et al (2006): A molecular link between the active component of marijuana and Alzheimer's disease pathology. . N. Engl. J.Med; 331 : 518 - 22.

Facciola S (2000): Cornucopia- A Source Book of Edible Plants. In Kampong Publications ISBN 0-9628087-0-9Excellent. Kampong, 20-25.

Fan P (1995): Cannabinoid Agonists Inhibit the Activation of 5-HT3 Receptors in Rat Nodose Ganglion Neurons, J. Neurophys ; 73 : 907-910.

Ferraro DP (2000): Acute effects of marijuana on human memory and cognition, in. Petersen R.C (ed.), Marijuana Research Findings, NIDA Research Monograph Washington, DC, US Government Printing Office, 31: 98-119.

Folen MR, Sidney S, Tekawa IS, et al.(1998): Health care use by frequent marijuana smokers who do not smoke tobacco West .J Med;158 : 596 - 601.

Fortner N, Fogerson R and Lindman D (1997): Marijauna positive urine test results from consumption of hemp seeds in food products. J Anal Toxicol (21): 476-481.

References

- Fride E and Mechoulam R (1993):*** Pharmacological Activity of the Cannabinoid Receptor Agonist, Anandamide, a Brain Constituent, *Europ. J. Pharmacol*; 231 : 313-314.
- Geschwinde TH (1996):*** The health and psychological consequences of cannabis use ,*Addiction* , 91(6): 759-773.
- Gier JJ (2000):*** A subjective measurement of the influence of ethyl/alcohol in moderate doses on real driving performances. *Blutalkohol*, 16: 363–370.
- Gieringer D (2001):*** Isolation, structure and partial synthesis of an active constituent of hashish, *J. Am. Chem. Soc*; (86):1646-1647.
- Glatt H. (1991):*** 1-Tetrahydrocannabinol and Δ^9 -Tetrahydrocannabinol : Mutagenicity Investigation in the Ames Test, *Mut . Res* , 66:329-35.
- Green K (2009):*** Marijuana smoking: Effects of varying puff volumes and breatholding duration, *J. Pharmacol and Experi .Therap* ; (272): 560-69.
- Guzmán M, Galve-Roperh I, Sánchez C, Cortés ML, Gómez del Pulgar T, Izquierdo M, et al. (2000):*** Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation *Nat. Med*.J; (3): 313-319.
- Hagers H (2002):*** *der Pharmazeutischen Praxis, Cannabis Monograph*, 5 edition, Springer, Berlin, 175-200.

References

Hall W, Solowij N, Lemon J et al. (1999): The Health and Psychological Consequences of Cannabis Use, National Drug Strategy Monograph Series No. 25 (Canberra, Australian Government Publication Service, 325-400.

Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E, et al. (1999): HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. *Proc Natl Acad Sci* , 96(25):14228-33.

Herkenham MA (1993): Localization of Cannabinoid Receptors in Brain: Relationship to Motor and Reward Systems. In: *Biological Basis of Substance Abuse*, Oxford Univ. Press, New York and London, pp. 187-200.

Hillig K (2005): A systematic investigation of *Cannabis*. Doctoral Dissertation. Department of Biology, Indiana University. Bloomington, Indiana. Published by UMI. Retrieved on 25 Feb 2007.

Hirst GW, O'Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, Amaro R, Rodriguez MJ, Chase V, Jeffers L, Schiff E, et al. (1998): Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liverdisease). *Am J Gastroenterol*; (8) : 2117 - 2119.

Hollister LE (1996): Health aspects of cannabis, *Pharmacol. Rev*, 38 : (1), 1-20.

Huber GL, Griffith DL and Langsjoen MP (1998): The effects of

References

- marijuana on the respiratory and cardiovascular systems, in Marijuana: An International Research Report, Chesher, G. Consroe P. and Musty R. (eds.), National Campaign Against Drug Abuse Monograph No. 7, Canberra, Australian Publishing Service, 3-18.
- Huestis MA, Henningfield GA and Cone EJ (1992):** Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta-9-THC and 11 – nor-9-carboxy-delta-9-THC (THCCOOH), J. Anal. Toxicol ; 16 : 283-290.
- Huw T (1993):** Psychiatric symptoms in cannabis users, B. J. S; 163: 141-149.
- Jessor, R (2009):** Psychosocial correlates of marijuana use and problem drinking in a national sample of adolescents. Am. J. Public Health, 70: 604-13.
- Jin KL, Mao XO, Goldsmith PC, Greenberg DA, et al. (2000):** CB₁ cannabinoid receptor induction in experimental stroke. Ann. Neurol J; 48 (2) : 257- 61.
- Job E (2000):** Dexanabinol Pharms Curr Opin Investig Drugs 1(4):494-503 Jpn J Pharmacol ; 84:229–236.
- Johnson D, Conradi A and McGuigan M. (1991):** Hashish ingestion in toddlers, Vet. Hum. Toxicol. 33: 393.
- Johnston LD (1995):** National survey results on drug use from the Monitoring the future study, Washington , DC, US Department of health and Human services.
-

References

- Julien RM (1997):*** Cognitive effects of marihuana. In: The use of marihuana; a psychological and physiological inquiry. Mendelson J;H., Rossi A. M. & Meyer R. E. (Eds.), New York: Plenum Press, (pp. 107-114).
- Kalant H, Leblanc AE, Gibbins RJ, et al. (2003):*** Tolerance to and dependence on, some non-opiate psychotropic drugs. Pharmacolol. Rev , 23, 135-158.
- Kapur B (1994):*** Drug-testing methods and interpretations of test result. In: Macdonald, S., Roman, P. (Eds.), Drug-testing in the workplace. New York: Plenum Press. 16:240-245.
- Kate S, (2003) :*** Cancer fighting cannabis : J Clin Psychopharmacol.; (3):305-313 .
- King L.A. (2004) :*** Cannabis potency in Europe, Addiction, 100: 884
- Kosten TR (1997):*** Substance-use disorders in DSM-III-R, British Journal of Psychiatry 151, 8-19.
- Kreuz DS and Axelrod J (1999):*** Delta-9-THC: Localization in body fat, Science, vol. 391 :1512-1517..
- Krowicki ZK, Moerschbaecher JM, Winsauer PJ, Digavalli SV, Hornby PJ, et al. (1999):*** Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur J Pharmacol; 371(2-3):187-96.
- Kuehnle JH, Mendelson K, David R, et al. (2007):*** Computed tomographic examination of heavy marijuana users, J . Ame . Med Associ ;vol (237): 1231-1232.

References

- Kunkel G (2000):** Plants for Human Consumption. Koeltz Scientific Books In: ISBN . A comprehensive listing of latin names with a brief list of edible parts. London , (69): 2998 -3822 .
- Lehmann TH (1995):** Chemical Profile of Cannnabis Sativa, Innaugural Dissertation, University of Berne, Berne. (4):1111-1114.
- Lichtman AH, Cook SA and Martin BR, et al. (1996):** Investigation of Brain Sites Mediating Cannabinoid -Induced Antinociception in Rats: Evidence Supporting Periaqueductal Gray Involvement, J. Pharmacol. Exper; Therap., 276 : 585-593.
- Macdonald S, Anglin-Bodrug K, Mann R, Erickson P, Hathaway A, Chipman M, Rylett M, et al. (2003):** Review: Injury risk associated with cannabis and cocaine use. Drug and Alcohol Dependence, 72 (2): 99-115.
- Macnab A, Anderson B and Susak L, (1989):** Ingestion of cannabis of coma in children. Pediatric Emerg Care 5: 238-239.
- Maes V, Charlier C, Grenez O, Verstraete A, et al. (1999):** Drugs and medicines that are suspected to have a detrimental impact on road user performance. www.rosita.org April 1, 2003.
- Malit LA, Johnstone RE, Bourke DI, Kulp RA, Klein V, Smith TC, et al. (2005):** Intravenous delta9-Tetrahydrocannabinol: Effects of ventilatory control and cardiovascular dynamics. Anesthesiology, 42(6):666-73.
- Mann RE, Vogel-Sprott M, Genest M, et al. (2001):** Alcohol and cognitions: some preliminary observations. Journal of Studies on Alcohol, (44):900-905.
-

References

- Martin BR and Cone EJ (1999):*** Chemistry and pharmacology of cannabis. In: Kalant, H., Corrigall, W., Hall, W., Smart, R. (Eds), The Health Effects of Cannabis. Toronto: Addiction Research Foundation, pp. 21-68.
- Martin BR and Hall W (1999):*** The Health Effects of Cannabis: Key Issues of Policy Relevance, Rev,38 (1): 1-20.
- Maykut MO (2004):*** Health consequences of acute and chronic marihuana use, Prog. NeuroPsychopharmacol. and Biol. Psychiat, 9(3):209- 238.
- McMeens RR (2002):*** Report of the committee on cannabis indica; from Transactions of the Fifteenth Annual Meeting of the Ohio State Medical Society, Follett, Foster and Co., Columbus, Ohio, 1860, pp. 75-100.
- Mechoulam R (1998):*** Recent advantages in cannabinoid research. Forsch Komplementarmed ,6 (13):16-20.
- Mechoulam R(2000):*** Marijuana chemistry: Recent advances open the area to more sophisticated biological research, Science,168: 1159-1166.
- Mechoulam R, Hanus L and Martin BR (1997) :*** The search for endogenous ligands of the cannabinoid receptor, Biochemical Pharmacology 48: 1537-1544.
- Mendelson JH (2005):*** Acute effects of marijuana smoking on prolactin levels in human females, Journal of Pharmacology and Experimental Therapeutics 232: 220-222.

References

- Miller P McC and Plant M (1996):*** Drinking, smoking and illicit drug use among 15 and 16 year olds Br . Med . J ;313: 394-397.
- Morgan JP and Zimmer L (1997):*** Marijuana Myths, Marijuana Facts: Rev of the scientific evidence, 40 (2): 7-12.
- Moskowitz H, (2002):*** Marihuana and Driving. *Accid. Anal. Prev.*, 17 (4), pages 323-345.
- Muller-V (2002):*** Treatment of Tourette's syndrome with Deltetrahydrocannabinol (THC): a randomized cross over trial. *Pharmacopsychiatry*, 35: 57-61.
- Neff A (2002):*** Preliminary observation with dronabinol in patient with intractable pruritus secondary to cholestatic liver disease . *Am J of Gastroenterol* , 97: 2117-2119.
- Newcome T and Bentler P (1998):*** Consequences of Adolescent Drug Use In: Impact on the Lives of Young Adults, Newbury Park, California, Sage Publications, (15): 2111-2115.
- Nicholson AN, Turner C, Stone BM, Robson PJ, et al. (2004):*** Effect of delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. *J Clin Psychopharmacol*; (3) : 305 - 313.
- Nolan M (2008):*** Cannabis. Toxicity of cannabis. *J . Art . Res*; (10):141-144.
- Notcutt W, Price M and Chapman G (1997):*** Clinical experience with nabiximol for chronic pain, *Pharmaceutical sciences*,(3): 551 –

555.

Novak K, Zitterl-Eglseer SG, Deans and Franz CM (2001): "Essential oils of different cultivars of *Cannabis sativa* L. and their antimicrobial activity", *Flavour and Fragrance Journal*;16 (4) : 259 - 262.

O’Kaneet CJ, Tutt DC, Bauer LA et al. (2002): Cannabis and driving: a new perspective. *Emergency Medicine*, 14(3):296-303.

Ofek O, Karsak M, Leclerc N, et al. (2006): Peripheral cannabinoid receptor, CB2 regulates Bone mass, *Prot Natl Acad Sci*, 103 (3):696-701.

Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E, et al. (2001): An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. 413(6855):527-31.

Perez – Reges M, Burstein SH, White WR, McDonald SA and Hicks RE (1991): Antagonism of marihana effects by indomethacin in human life sciences 48 (6) : 507 – 515.

Pertwee RG ,Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, , Ross RA, Mechoulam R, Fride E, et al. (1999): HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. *Proc Natl Acad Sci* , 96(25):14228-33.

Polen M (2003): Health care use by frequent marijuana smokers who do not smoke tobacco, *West. J. Med;* (158): 596-601.

References

- Pope H and Yurgelun-Todd D (1996):*** The residual cognitive effects of heavy marijuana use in college students, *Journal of Psychoactive Drugs*; 20: 57-65.
- Potts SG and Nolan M (2008):*** Pharmacology of cannabis . *N. Engl. J. Med*;331 : 518-22.
- Ramaekers JG (2002):*** “Performance impairment and risk of motor vehicle crashes after cannabis use” in Pelc, I. (ed.) *International Scientific Conference on Cannabis*, Brussels, p 81.
- Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML, et al. (2005):*** Prevention of Alzheimer's disease pathology by cannabinoids: *J Neurosci*; 25(8) : 1904 - 1913 .
- Reid BE (1997):*** *Famine Foods of the Chiu-Huang Pen-ts'ao*. Taipei. Southern Materials Centre A translation of an ancient Chinese book on edible wild foods. Fascinating.
- Reynolds J and Russel L (2004):*** "Therapeutical uses and toxic effects of cannabis indica, *Lancet*, 11 :637-38, 22.
- Robbe HWJ (1994).*** Influence of Marijuana on Driving. PhD thesis, Institute for Human Psychopharmacology, University of Limburg, Maastricht.
- Robinson LI (1999):*** Maternal drug use and the risk of childhood non lymphoblastic leukemia among offspring: An epidemiologic investigation implicating marijuana, *Cancer*, (63): 1904-1911,
- Rog DJ, Nurmikko TJ, Friede T, Young CA, et al. (2005):*** Randomized, controlled trial of cannabis-based medicine in
-

References

central pain in multiple sclerosis. *Neurol* ; 65(6): 812-819.

Rosenkrantz H (2003): Cannabis, marijuana, and cannabinoid toxicological manifestations in man and animals, in Cannabis and Health Hazards: Proceedings of an ARF/WHO Scientific Meeting on Adverse Health and A. Weil, Adverse reactions to marijuana, *NEJM*; (282): 997-1000.

Sasman M (1998): Cannabis indica in pharmaceuticals, *J. of the N.J. Med Soc*; 35:51-52.

Schiffrin EL (2001): A critical review of the role of endothelial factors in the pathogenesis of hypertension. *J Cardiovasc Pharmacol*; 38 (2):53-55.

Solowij N (1991): Effects of long-term cannabis use on selective attention: An event-related potential study, *Pharmacology, Biochemistry and Behaviour* , (40) : 683-688.

Spruit, I. P. (2009): International Scientific Conference on Cannabis, Ministry of Public Health of Belgium, Brussels.

Stein IN. (1988): Marijuana testing. *West. J. Med.* 148-78.

Strumpler RE, Nelson G and Urry FM (1997): Positive cannabinoid workplaces drug test. *Anal Toxicol* (21): 283-285.

Swift W, Hall W, Teesson M. et al (2005): Survey of Australians using cannabis for medical purposes. *Harm Reduct J*; (4) : 2 - 18.

Tashkin DP (1999): Cannabis effects on the respiratory system, in Kalant, H. (eds), In :The Health Effects of Cannabis,1999, London, pp 121-124.

References

Tashkin DP (2007): Acute effects of smoked marijuana and oral delta-9-thc on specific airway conductance in asthmatic subjects, *Am Rev Respir Dis* ,109: 420-8.

Theus L (2009): Effects of marijuana on the lung and its defenses against infection and cancer, *School Psychology International* (20): 23-37.

Thompson LJ and Proctor RC (2003): The use of pyrahexyl in the treatment of alcoholic and drug withdrawal conditions, *N. Carolina Med. J.* (14) :520-23.

Tzambazis K and Stough C (2002): The SFST and driving ability. Are they related? In: D.R. Mayhew and C. Dussault (Eds.), *Alcohol, Drugs and Traffic Safety – T'2002*. Quebec: société de l'assurance automobile du Québec.PP 242-245.

Volfe Z, Dvilansky A and Nathan I (1995): Cannabinoids Block Release of Serotonin from Platelets by Plasma from Migraine Patients, *Int. J. Clin. Pharm. Res*;(4): 243-246.

Vratislav S (1995). *Endocrinology 1994-1995. Casopis Lekaru Ceskych* (Czech Republic), 134: 535-536.

Wall ME and Zancy BM (2006): Sadler Metabolism, disposition and kinetics of delta-9-THC in men and women, *Clin. Pharmacol. Ther*;34 (3): 352-363.

Walther S, Mahlberg R, Eichmann U, Kunz D, et al. (2006): Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.... *Pharmacopsychiatry*; 185(4):524-528.

References

Webb E, Ashton CH, Kelly P, et al. (1996): Alcohol and drug use in UK university students. *Lancet*,348: 922-925.

Weil WL (2000): Cannabinoid pharmacology, *Pharmacol. Rev.*, 38(2): 151-178.

Witter FR and Niebyl JR (2000): Marijuana use in pregnancy and pregnancy outcome, *Ame . J of Perinatol*; (7):121-125.

Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M and Ward S(2005): Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. In *Gastroenterol*, 129(2):437-53.